New research published online today in the American Journal of Psychiatry finds that low-dose buprenorphine, given after a single ketamine infusion, significantly sustained reductions in suicidal ideation in adults with major depressive disorder. The randomized, double-blind, placebo-controlled trial is the first to show that a pharmacologic intervention may help maintain and build on ketamine’s anti-suicidal effects in this at-risk population.

A new study led by Curtin University has revealed millions of dementia cases across the Western Pacific Region could potentially be prevented by implementing country-specific strategies to address key risk factors such as education access, obesity and mental health.